Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Naber

Showing results (111-120 of 195) with videos related to

Pageof 20
Sort By:
Pharmacopsychiatry|July 9, 2009
Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophreniaD Suarez, J M Haro, D Novick, et al.
Psychopharmacology|January 1, 1986
Neuroendocrine effects of clonidine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathologyF Müller-Spahn, M Ackenheil, M Albus, et al.
Pharmacopsychiatry|July 14, 2011
Applicability of the Clinical Global Impressions-Aggression (CGI-A) scale for use in file audit trialsC G Huber, D Schöttle, M Lambert, et al.
Pharmacopsychiatry|May 1, 1986
Clinical and biochemical effects of nicergoline in chronic schizophrenic patientsM Albus, C Botschev, F Müller-Spahn, et al.
Pharmacopsychiatry|February 1, 2012
Are ratings on the positive and negative syndrome scale for schizophrenia biased by personality traits?C G Huber, A Hoppe, A Agorastos, et al.
Biological Psychiatry|October 1, 1985
Tardive dyskinesia: relation to computer-tomographic, endocrine, and psychopathological variablesM Albus, D Naber, F Müller-Spahn, et al.
Biological Psychiatry|May 2, 2001
Leptin: a modulator of alcohol craving?F Kiefer, H Jahn, M Jaschinski, et al.
Psychiatry Research|October 1, 1982
Response of plasma beta-endorphin immunoreactivity to d-amphetamine and placebo in schizophrenic patientsS C Schulz, D P van Kammen, D Pickar, et al.
Psychopharmacology Bulletin|October 1, 1982
beta-Endorphin, cortisol, and prolactin in serum of schizophrenic patients during long-term neuroleptic treatment and after withdrawal: relationships to psychopathologyD Naber, M Albus, F Muller, et al.
Neuroreport|May 27, 1997
Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptorM Rietschel, D Naber, R Fimmers, et al.
Pageof 20

Showing results (111-120 of 195) with videos related to

Sort By:
Pageof 20
Pharmacopsychiatry|July 9, 2009
Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophreniaD Suarez, J M Haro, D Novick, et al.
Psychopharmacology|January 1, 1986
Neuroendocrine effects of clonidine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathologyF Müller-Spahn, M Ackenheil, M Albus, et al.
Pharmacopsychiatry|July 14, 2011
Applicability of the Clinical Global Impressions-Aggression (CGI-A) scale for use in file audit trialsC G Huber, D Schöttle, M Lambert, et al.
Pharmacopsychiatry|May 1, 1986
Clinical and biochemical effects of nicergoline in chronic schizophrenic patientsM Albus, C Botschev, F Müller-Spahn, et al.
Pharmacopsychiatry|February 1, 2012
Are ratings on the positive and negative syndrome scale for schizophrenia biased by personality traits?C G Huber, A Hoppe, A Agorastos, et al.
Biological Psychiatry|October 1, 1985
Tardive dyskinesia: relation to computer-tomographic, endocrine, and psychopathological variablesM Albus, D Naber, F Müller-Spahn, et al.
Biological Psychiatry|May 2, 2001
Leptin: a modulator of alcohol craving?F Kiefer, H Jahn, M Jaschinski, et al.
Psychiatry Research|October 1, 1982
Response of plasma beta-endorphin immunoreactivity to d-amphetamine and placebo in schizophrenic patientsS C Schulz, D P van Kammen, D Pickar, et al.
Psychopharmacology Bulletin|October 1, 1982
beta-Endorphin, cortisol, and prolactin in serum of schizophrenic patients during long-term neuroleptic treatment and after withdrawal: relationships to psychopathologyD Naber, M Albus, F Muller, et al.
Neuroreport|May 27, 1997
Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptorM Rietschel, D Naber, R Fimmers, et al.
Pageof 20